Kentucky Injury Lawyers

Another Verdict Against Actos

Published on Oct 24, 2014 at 8:12 am in Dangerous Drugs.

Kentucky Pharmaceutical AttorneyA state jury in Pennsylvania has ordered Takeda Pharmaceuticals to pay a woman more than $2 million who claimed the company’s diabetes drug, Actos, gave her bladder cancer.

The plaintiff is a 79-year-old retired accountant. She is the seventh Actos patient to bring her case to trial.

The U.S. Food & Drug Administration approved the use of Actos in 1999 to treat Type 2 diabetes. In 2011, the FDA warned that the use of Actos for more than one year may be linked to bladder cancer. In fact, long-term studies had shown that Actos use for more than one year increased a patient’s chances of getting cancer by as much as 40 percent.

Levaquin – Johnson & Johnson Faces Second Round of Lawsuits

Published on Oct 23, 2014 at 8:00 am in Dangerous Drugs.

Johnson & Johnson is facing another round of lawsuits by users of its antibiotic Levaquin. Levaquin, a powerful antibiotic, was once the highest selling antibiotic in the country. However, more evidence has mounted that the drug causes nerve damage that can be permanent, even with short-term use.

The company faced thousands of lawsuits after the FDA issued its first 2009 warning that use of the drug can cause tendon ruptures and tendonitis. This risk was said to be higher for those over 60 and people also taking steroids. J&J won some and lost some of those early cases, at times the jury sided with the patients, at times they thought the warnings put on the labels were adequate.

The drug is manufactured by J&J’s subsidiary, Ortho-McNeil-Janssen Pharmaceuticals. The company has always maintained that it properly disclosed the risks associated with the drug, which has been prescribed to millions of patients.

Levaquin Use Linked To Nerve Damage

Published on Oct 22, 2014 at 11:58 am in Dangerous Drugs.

A new study has shown that users of the antibiotic Levaquin and other drugs in its class can cause permanent nerve damage. Levaquin is manufactured by the Johnson and Johnson subsidiary Ortho-McNeil Pharmaceutical, Inc.

Levaquin is the brand name for the antibiotic levofloxacin. It is commonly used to treat infections in the prostate, urinary tract, and diabetic foot infections. It is part of a class of powerful antibiotics called fluoroquinolones. Other fluoroquinolone drugs include Cipro, Avelox, Noroxin, Floxin, and Factive.

While all antibiotics can present a risk of side effects, the fluoroquinolones are unique in their potential to penetrate the blood-brain barrier. This allows the drug to enter the brain and possibly damage the central nervous system.

Makers of Xarelto Sued for Internal Bleeding

Published on Oct 14, 2014 at 1:56 pm in Dangerous Drugs.

Liable Drug ManufacturersLawsuits have been filed in state and federal court by plaintiffs who suffered serious internal bleeding after taking Xarelto. The anti-clotting drug is manufactured by the German drug giant Bayer. Xarelto is distributed in the U.S. by Johnson & Johnson subsidiary Janssen Pharmaceuticals.

Xarelto is a blood thinner. The anti-clotting drug is one of Bayer’s top five medicines and it earned $1.3 billion in sales last year.

The lawsuits charge that the companies failed to warn users that Xarelto could result in irreversible internal bleeding. Xarelto has been marketed as a more convenient choice than warfarin (Coumadin), which is used as an anticoagulant in the U.S. since the 1950s. Warfarin requires patients to take frequent blood tests and follow a strict diet. However, warfarin’s anticoagulation is reversible by administering Vitamin K. Xarelto does not have a known reversal agent and many of the serious bleeding incidents have led to death.

Judge Accuses Takeda of Destroying Actos Evidence

Published on Aug 6, 2014 at 8:41 am in Dangerous Drugs.

Last Spring, a federal jury found that the makers of the diabetes drug Actos knew about and concealed the drug’s cancer risks. The plaintiff in that case was a New York man who claims his bladder cancer was caused by Actos.

The jury awarded the plaintiff $1.5 million in compensatory damages and, additionally, a $9 billion punitive damages award was ordered against the manufacturers. This amounted to $6 billion against Japan-based Takeda Pharmaceuticals and $3 billion against Eli Lilly, which co-marketed the drug.

After the trial, charges have been made that Takeda’s company and its lawyers concealed evidence. In late June, the judge formally admonished Takeda for destroying evidence in the case. A later decision will consider attorney misconduct regarding Takeda’s defense team.

Actos is the brand name of the prescription drug pioglitazone, which was approved by the FDA to treat Type 2 diabetes in 1999. In July 2011, the FDA issued a warning that Actos “may be associated with an increased risk of bladder cancer” after use for more than one year. This came after long-term studies showed not just a cancer link, but a high cancer link – patients who used Actos for more than one year had up to a 40% increased chance of developing cancer.